Literature DB >> 6973952

In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type b.

R Yogev, C Melick, W J Kabat.   

Abstract

Eight strans of ampicillin-resistant beta-lactamase-producing Haemophilus influenzae type b were studied in vitro for synergy between amoxicillin and clavulanic acid. The minimal inhibitory concentrations for amoxicillin alone were 6.25 to 12.5 microgram/ml, and for clavulanic acid alone they were 12.5 to 25 microgram/ml. However, seven of eight strains were inhibited by a combination of 0.36 microgram of amoxicillin and 0.36 microgram of clavulanic acid per ml. Infant rat models of bacteremia and meningitis were used to test the efficacy of amoxicillin and clavulanic acid alone and in combination upon four strains of ampicillin-resistant H. influenzae. Neither amoxicillin alone (27 animals) nor clavulanic acid alone (20 animals) sterilized the blood or cerebrospinal fluid of the animals. In contrast, 30 of 33 blood cultures and 29 of 33 cerebrospinal fluid cultures were sterile when a combination of the two drugs in the same dosages was used. The observed in vitro and in vivo synergism between amoxicillin and clavulanic acid suggests that the combination may be effective therapy for invasive infections in humans caused by ampicillin-resistant H. influenzae type b.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6973952      PMCID: PMC181597          DOI: 10.1128/AAC.19.6.993

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.

Authors:  A P Ball; A M Geddes; P G Davey; I D Farrell; G R Brookes
Journal:  Lancet       Date:  1980-03-22       Impact factor: 79.321

2.  The influence of clavulanic acid on the susceptibility to amoxycillin of beta-lactamase producing strains of H. influenzae using different inoculum sizes.

Authors:  B Van Klingeren; M Dessens-Kroon
Journal:  J Antimicrob Chemother       Date:  1979-05       Impact factor: 5.790

3.  R-factor mediated beta-lactamase production by Haemophilus influenzae.

Authors:  R B Sykes; M Matthew; C H O'Callaghan
Journal:  J Med Microbiol       Date:  1975-08       Impact factor: 2.472

4.  Beta-lactamase activity in ampicillin-resistant Haemophilus influenzae.

Authors:  W E Farrar; N M O'Dell
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

5.  Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid.

Authors:  J Fisher; R L Charnas; J R Knowles
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

6.  Chemical studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid.

Authors:  R L Charnas; J Fisher; J R Knowles
Journal:  Biochemistry       Date:  1978-05-30       Impact factor: 3.162

7.  Soft-tissue infections of ampicillin-resistant Haemophilus influenzae type b. The use of ampicillin and nafcillin in their treatment.

Authors:  R Yogev
Journal:  Am J Dis Child       Date:  1981-05

8.  Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains.

Authors:  M Matsuura; H Nakazawa; T Hashimoto; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  Synergistic action of ampicillin and nafcillin against ampicillin-resistant Haemophilus influenzae.

Authors:  R Yogev; E Burkholder; A T Davis
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

10.  Synergistic action of nafcillin and ampicillin against ampicillin-resistant Haemophilus influenzae type b bacteremia and meningitis in infant rats.

Authors:  R Yogev; W J Kabat
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

  10 in total
  8 in total

1.  Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients.

Authors:  U B Schaad; P A Casey; D L Cooper
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

Review 2.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

3.  In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits.

Authors:  P C Fuchs; A L Barry; C Thornsberry; T L Gavan; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

4.  Amoxicillin-clavulanic acid in the treatment of lower respiratory tract infections caused by beta-lactamase-positive Haemophilus influenzae and Branhamella catarrhalis.

Authors:  R J Wallace; L C Steele; D L Brooks; J I Luman; R W Wilson; J W McLarty
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

5.  In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.

Authors:  F A Sarubbi; A Verghese; C Caggiano; S Holtsclaw-Berk; S L Berk
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

6.  Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid.

Authors:  G A Roselle; R Bode; B Hamilton; M Bibler; R Sullivan; R Douce; J L Staneck; W E Bullock
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

7.  In vitro activity of BRL 17421 against Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis.

Authors:  P Piot; E Van Dyck
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.

Authors:  Nathan E Stone; Sierra A Jaramillo; Ashley N Jones; Adam J Vazquez; Madison Martz; Lora M Versluis; Marlee O Raniere; Haley E Nunnally; Katherine E Zarn; Roxanne Nottingham; Ken R Ng; Jason W Sahl; David M Wagner; Steen Knudsen; Erik W Settles; Paul Keim; Christopher T French
Journal:  mBio       Date:  2021-01-19       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.